Related Experiment Video
Updated: Dec 24, 2025

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Cardiogenic Shock in Patients with Advanced Chronic Heart Failure
Cesar Y Guerrero-Miranda1, Shelley A Hall1
1BAYLOR SCOTT & WHITE RESEARCH INSTITUTE, DALLAS, TEXAS; BAYLOR UNIVERSITY MEDICAL CENTER, DALLAS, TEXAS; TEXAS A&M HEALTH SCIENCE CENTER, DALLAS, TEXAS.
Insights
Managing cardiogenic shock (CS) in advanced heart failure (HF) presents unique challenges. Early multidisciplinary assessment is crucial for timely intervention and advanced therapy candidacy in these complex patients.
Area of Science:
- Cardiology
- Critical Care Medicine
Background:
- Patients with end-stage heart failure (HF) refractory to medical therapy present distinct challenges compared to those with cardiogenic shock (CS) from myocardial infarction.
- Progression to refractory CS in advanced HF is linked to poor outcomes due to recognition, intervention, and salvage option difficulties.
Purpose of the Study:
- To review the definition, phenotypes, and classification of CS in advanced HF patients.
- To discuss the role of temporary mechanical circulatory support and the CS team in managing these complex cases.
Main Methods:
- This review synthesizes current literature on CS in advanced HF.
- Key aspects discussed include CS heterogeneity, diagnostic challenges, and treatment escalation strategies.
Main Results:
- CS in advanced HF is heterogeneous with varied etiologies, onset, hemodynamics, and end-organ effects.
- A universal definition for CS in this population is lacking, complicating management.
- Blunted hemodynamic response is common due to prolonged compensatory mechanisms.
Conclusions:
- Advanced HF patients in CS require a multidisciplinary team approach for timely assessment and escalation of care.
- Evaluating candidacy for temporary mechanical circulatory support and advanced therapies is critical.
Abstract:
Patients with end-stage heart failure (HF) who have failed optimal medical therapy provide a unique set of challenges compared to the more prevalent population of patients with cardiogenic shock (CS) due to ST-segment elevation myocardial infarction. Progression from "preshock" into a refractory state of CS is associated with a dismal outcome due to difficulties with the patient's recognition, response to interventions, and candidacy for salvage options. Challenges include heterogeneity of CS (eg, different phenotypes, etiologies, duration, acuity of onset, hemodynamics, end-organ effects), lack of a universal definition of CS that is applicable to this patient population, and blunted hemodynamic response given the patient's prolonged compensatory state. Individuals with advanced HF in CS require a multidisciplinary team-based assessment regarding when to escalate from medical therapy into temporary mechanical circulatory support, and they need an eligibility evaluation to determine their candidacy for advanced therapy. In this review, we discuss the definition and clinical phenotypes of CS, classification of CS in advanced HF patients, the utility of temporary mechanical circulatory support, and the role of the CS team.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure IV: Classification and Diagnostic Evaluation
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Pathophysiology of Heart Failure
Heart Failure V: Medical Management
Heart Failure I: Introduction

